News
BICTF
0.031
NaN%
--
Weekly Report: what happened at BICTF last week (0908-0912)?
Weekly Report · 09/15 11:00
Weekly Report: what happened at BICTF last week (0901-0905)?
Weekly Report · 09/08 11:02
Weekly Report: what happened at BICTF last week (0825-0829)?
Weekly Report · 09/01 10:58
Weekly Report: what happened at BICTF last week (0818-0822)?
Weekly Report · 08/25 11:07
Weekly Report: what happened at BICTF last week (0811-0815)?
Weekly Report · 08/18 11:00
Weekly Report: what happened at BICTF last week (0804-0808)?
Weekly Report · 08/11 11:06
Weekly Report: what happened at BICTF last week (0728-0801)?
Weekly Report · 08/04 11:09
Weekly Report: what happened at BICTF last week (0721-0725)?
Weekly Report · 07/28 11:10
Weekly Report: what happened at BICTF last week (0714-0718)?
Weekly Report · 07/21 11:00
Weekly Report: what happened at BICTF last week (0707-0711)?
Weekly Report · 07/14 11:09
Weekly Report: what happened at BICTF last week (0630-0704)?
Weekly Report · 07/07 11:01
Weekly Report: what happened at BICTF last week (0623-0627)?
Weekly Report · 06/30 11:07
Weekly Report: what happened at BICTF last week (0616-0620)?
Weekly Report · 06/23 11:00
Weekly Report: what happened at BICTF last week (0609-0613)?
Weekly Report · 06/16 11:06
Weekly Report: what happened at BICTF last week (0602-0606)?
Weekly Report · 06/09 11:08
Weekly Report: what happened at BICTF last week (0526-0530)?
Weekly Report · 06/02 11:16
Weekly Report: what happened at BICTF last week (0519-0523)?
Weekly Report · 05/26 11:15
Weekly Report: what happened at BICTF last week (0512-0516)?
Weekly Report · 05/19 11:06
Weekly Report: what happened at BICTF last week (0505-0509)?
Weekly Report · 05/12 11:07
Weekly Report: what happened at BICTF last week (0428-0502)?
Weekly Report · 05/05 11:09
More
Webull provides a variety of real-time BICTF stock news. You can receive the latest news about Biocure Technolo through multiple platforms. This information may help you make smarter investment decisions.
About BICTF
Biocure Technology Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. Additionally, the Company is developing biosimilar technologies for cancer treatment. The Company’s products include Interferon Beta, Ranibizumab and PEG-Filgrastim.